$ixhl so heavy in here
Incannex is trading at deep discount to cash value ($75M cash, $38M market cap) with zero debt and active buyback. Two Phase 2 drugs (PSX-001 for anxiety at 83% efficacy with FDA Fast Track; IHL-42X for sleep apnea at 83% efficacy) face favorable policy tailwinds and represent separate billion-dollar markets. Low float from 1:30 reverse split creates explosive upside potential on volume return or acquisition by major pharma.